Would you like to take some more ruxolitinib after your fedratinib?

被引：0

作者：

Ianotto, Jean-Christophe ^{[1
]}

机构：

[1] Univ Hosp Brest, Inst Oncol & Haematol, Dept Haematol, Bld Tanguy Prigent, F-29609 Brest, France

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2024年 / 205卷 / 04期

关键词：

fedratinib; myelofibrosis; ruxolitinib; SINGLE-ARM; OPEN-LABEL; MYELOFIBROSIS; EFFICACY; SAFETY; PHASE;

D O I：

10.1111/bjh.19695

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In Europe, ruxolitinib and fedratinib are the only JAK2 inhibitors available in local pharmacies. According to trial data, myelofibrosis patients should mostly receive ruxolitinib as first-line treatment and fedratinib in case of failure or intolerance (depending on their profile). Is it possible to reverse the choice of these drugs? Commentary on: Palandri et al. Ruxolitinib after Fedratinib failure in patients with myelofibrosis: a real-world case series. Br J Haematol 2024 (Online ahead of print). doi: 10.1111/ bjh.19654.

引用

页码：1253 / 1254

页数：2